Axios HQ & Qwoted Partner to Transform Data-Driven Storytelling
NEW YORK, NY - May 19, 2025 ( NEWMEDIAWIRE ) - Qwoted, the network for newsmakers, connecting thousands of journalists with experts and brands, is excited to announce a new partnership with Axios HQ, the company known for its innovative Smart Brevity(R) communication methodology.
As a kickoff to their ongoing collaboration, the two organizations will host a Tech Week 2025 event on June 5 in New York City. As part of Qwoted's Media Mixer series, the event will bring together leading voices in PR, business, and media to build relationships and connect with tech leaders and venture capitalists.
Qwoted CEO Dan Simon noted the partnership's benefits: 'Our mission has always been to empower communication professionals and journalists with tools that make their work easier and more impactful. Our partnership with Axios HQ is an important step toward this goal by integrating their communication methodologies into our innovative tech. I can't think of a better time to launch this partnership than NYC Tech Week.'
Axios HQ CMO Chris Willis added, 'At Axios HQ, we're committed to simplifying and elevating communication. That makes Qwoted a natural partner for us. This collaboration is a win-win for the entire ecosystem, and we're excited to introduce it during Tech Week.'
The organizations' affiliation will continue throughout 2025, providing Qwoted users access to Axios HQ's Smart Brevity(R) tools during the pitching process. At the same time, Axios HQ will begin incorporating Qwoted's data into its editorial pipeline to inform its strategies and storytelling capabilities.
Together, Qwoted and Axios HQ are setting a new standard for how PR professionals pitch and how companies create stories in a rapidly evolving industry.
About Qwoted
Qwoted uses innovative technology to connect PR professionals and journalists, making it easier to create better stories together. Trusted by hundreds of thousands of media and communications professionals, Qwoted offers valuable insights and tools to empower the PR and media community. Learn more at https://www.qwoted.com/.
About Axios HQ
Axios HQ helps organizations communicate more effectively - with software, training, and editorial consulting. Our team has merged a decade of Axios and Axios HQ's human expertise, proprietary data, and comms best practices with cutting-edge AI, all proven to help any leader strengthen internal comms, better achieve business goals, and amplify workforce connection. Nearly 1,000 organizations trust Axios HQ for their vital communications, from American Airlines and bp to the University of South Carolina and the U.S. Chamber of Commerce. Built for communicators by communicators - Axios HQ breaks through. For more information, or to schedule a demo, visit www.axioshq.com.
Media Contact
Liz Sweeney
Public Relations Manager
Qwoted
[email protected]
https://www.qwoted.com
View the original release on www.newmediawire.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 days ago
- Yahoo
AI systems may make mistakes now but are quickly getting smarter: Hinton
TORONTO — If mistakes artificial intelligence make have you doubting it can't ever rival humans, one of the technology's pioneers says you should think again. Geoffrey Hinton says AI keeps getting better at reasoning and has surpassed the skill level many experts expected it to be at by 2025. Yet every time the technology messes up, he says people have an itch to conclude that AI didn't understand what was being asked of it. The way he sees it is that AI can solve simple, immediate problems, but stumbles on anything more complicated like humans do. While improving the technology so it is not tripped up by anything complicated will be a challenge, he says it's more of a stumbling block than a hurdle that can't be overcome. Hinton's remarks were made at the University of Toronto, where he was speaking at one of the 300 events that make up the inaugural Toronto Tech Week. This report by The Canadian Press was first published June 25, 2025. Tara Deschamps, The Canadian Press Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 days ago
- Yahoo
tick Trading Software AG: Net Income up 123% in the First Half of 2024/25 - Full-Year Forecast Confirmed
DUSSELDORF, Germany - June 25, 2025 (NEWMEDIAWIRE) - Business performance at tick Trading Software AG (ISIN: DE000A35JS99) was clearly positive in the first half of the 2024/25 fiscal year. The provider of software for securities trading and settlement benefited in particular from the volatile capital market environment at the end of the reporting period (October 1, 2024 - March 31, 2025). Trading activity increased sharply for most customers, and with it the load-dependent revenues of tick-TS AG. Due to the strong increase in earnings for the period, the forecast for the full year 2024/25 was raised at the end of the reporting period and confirmed with the publication of the half-year report. tick-TS AG increased its revenue in the first half of the 2024/25 financial year by 17.6% to EUR 4,696 thousand. The growth driver was the "Load-dependent revenue" segment, where revenue rose from EUR 1,336 thousand to EUR 2,173 thousand. Costs remained stable overall. Earnings development was correspondingly positive in the reporting period. tick-TS AG increased its net income for the period, the company's financial performance indicator, by 122.5% from EUR 526 thousand to EUR 1,170 thousand between October 2024 and March 2025. The annual forecast raised on March 18, 2025, is confirmed: The Management Board expects an annual net income of between EUR 1,300 thousand and EUR 1,700 thousand for the full year 2024/25, representing an improvement in earnings compared to the 2023/24 fiscal year. This means that the dividend (most recently EUR 0.50 per share) is also likely to be increased again. In the second half of the fiscal year, the company is not expected to be able to fully match the strong performance seen in the reporting period. The reason: In April 2025, a top customer informed tick-TS AG that the order flow would be gradually reduced, but to a large extent, starting in May 2025. As a result, a reduction in monthly sales of 15 to 20% is expected. The company is currently still in talks with the customer about further cooperation. Once these talks have been concluded, the forecast for the current year will be finalized and a forecast for 2025/26 will be published. At the same time, the company sees opportunities for new business with existing and potential new customers to partially offset the expected decline in sales. The half-year financial report (German version only) for the 2024/25 fiscal year is available for download at under Investor Relations/Facts and Figures. About tick Trading Software AG With the TradeBase Multi Exchange platform (TBMX), tick-TS AG has been successfully providing its professional customers with one of the world's most advancedand reliable trading platforms for more than 20 years. The product portfolio includes direct connections to national and international marketplaces and brokers, market making tools for designated sponsoring, a proprietary hosting and housing infrastructure and the e-Trading Compliance Monitor (ECM) for compliance with ESMA regulations. tick-TS AG has been listed on the primary market (Regulated Unofficial Market) of the Dusseldorf Stock Exchange since 2017 (ISIN: DE000A35JS99, ticker symbol: TBX0) and is available on many other trading venues. A special feature is the payment of the entire distributable net profit as a dividend to investors, as stipulated in the company's Articles of Association. Contacttick Trading Software AGBerliner Allee 5940212 ir@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
6 days ago
- Associated Press
Axim Biotechnologies Files Pre-Submission With FDA for CLIA Waiver Pathway on Lactoferrin Point-of-Care Diagnostic Test
SAN DIEGO, CA - June 24, 2025 ( NEWMEDIAWIRE ) - Axim Biotechnologies, Inc. (OTCQB: AXIM), a leading developer of rapid diagnostic testing for ocular and systemic conditions, today announced that it has filed a Pre-Submission (Pre-Sub Q) with the U.S. Food and Drug Administration (FDA) as the first formal step in seeking a Clinical Laboratory Improvement Amendments (CLIA) Waiver for its rapid, point-of-care Lactoferrin diagnostic test (TearScan Lf). Axim's TearScan Lf is the first and only FDA 510 (k)-cleared point-of-care (POC) diagnostic test specifically intended to support the diagnosis of Aqueous Deficient Dry Eye Disease (ADDE). Lactoferrin tear levels are a convenient POC diagnostic that aids in determining the viability of the lacrimal gland. Lactoferrin levels are reduced in 80% of patients with ADDE. By distinguishing ADDE from other forms of Dry Eye Disease, the test helps avoid trial-and-error use of therapies that are ineffective for tear deficiency. Additionally, because Lactoferrin levels reflect lacrimal gland function, repeated testing allows the physician to monitor response to treatment and disease progression over time. The Pre-Sub Q process allows device developers to engage early with the FDA to receive feedback, clarify regulatory expectations, and minimize risks of delays during the formal waiver application. FDA feedback is anticipated within 60 days. Upon FDA feedback, the company plans to conduct a comparative clinical study to support its CLIA Waiver Application, which is expected to be submitted later this year. The FDA typically completes review of CLIA Waiver Applications within 90 days. Currently, facilities must obtain CLIA certification and adhere to laboratory protocols in order to administer Axim's Lactoferrin test. A CLIA waiver would eliminate the certification requirement and enable administration of the point-of-care Lactoferrin test by ophthalmologists and optometrists in non-laboratory settings thereby allowing for far broader clinical use and accelerating commercial adoption. 'The Company's Pre-Sub Q submission marks a significant milestone in its strategy to broaden access to its tests by obtaining a CLIA waiver. We are committed to making it easier for eye care providers to integrate our tests into their practices without complex lab infrastructure,' said Catalina Valencia, CEO of Axim Biotechnologies. 'Today's submission is the first step in that process, and we believe it will open the door to widespread use of our Lactoferrin test - and soon after, our IgE test - in primary eye care and beyond. We believe that securing CLIA waivers for our Lactoferrin and IgE tests will be transformative, unlocking significant commercial opportunities in the U.S. market and enabling earlier, more accessible diagnosis of Dry Eye Disease, including ADDE and ocular allergy. As a CLIA waived, semi‑quantitative, point-of-care biomarker test, TearScan Lf would be well-positioned to capture market share in the diagnostic device segment for Dry Eye.' About AXIM(R) Biotechnologies Founded in 2014, AXIM(R) Biotechnologies, Inc. (AXIM) is a vertically integrated research and development company focused on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease (DED) through rapid diagnostic tests. The Company owns two of the only five FDA Cleared Diagnostic tests for Dry Eye Disease. For more information, please visit Corporate/Media Contact Info: +1 858-256-5132 [email protected] Forward-Looking Statements The statements made by Axim Biotechnologies Inc., in this press release may be 'forward-looking' in nature within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe Axim's future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Axim Biotechnologies, Inc. Actual results could differ materially from those projected due to there being no assurance that our diagnostic candidate will ever be approved for use by the U.S. FDA or any equivalent foreign regulatory agency. Further, Axim's eye care diagnostic products that are FDA cleared may not be manufactured in large enough quantities or that third parties with established eye care physicians will enter into agreements or purchase from the Company, and even if the Company's diagnostic candidates are successful, they may generate only limited revenue and profits for the Company. Various other factors are detailed from time to time in Axim's Reports filed on Axim Biotechnologies, Inc., undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, unless otherwise required by law. View the original release on
